NASDAQ$BEAM
Beam Therapeutics Inc. · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Beam Therapeutics' financial results for Q4 2023 and year-end were reported, with key milestones reiterated across its sickle cell disease and genetic disease portfolios.
Beam Therapeutics reported a net income of $142.8 million for the fourth quarter of 2023, with cash, cash equivalents, and marketable securities totaling $1.2 billion. The company anticipates key milestones for BEAM-101, ESCAPE, BEAM-301, and BEAM-302, and expects cash runway to support operating plans into 2027.
- Patient dosing and enrollment are progressing in the BEACON Phase 1/2 study of BEAM-101 in severe sickle cell disease, with initial clinical data expected in the second half of 2024.
- A Phase 1 trial initiation for BEAM-302 in alpha-1 antitrypsin deficiency is on track for the first half of 2024, pending European Clinical Trial Application (CTA) acceptance.
- The company ended the fourth quarter of 2023 with $1.2 billion in cash, cash equivalents, and marketable securities, which is expected to support operating plans into 2027.
- Beam expects to initiate its first in vivo clinical studies and report the first in-human data from its ex vivo base editing clinical programs in 2024.
Headline financials
Revenue & EPS history
Beam Therapeutics · Revenue · Quarterly
$316M
Revenue by segment
Beam Therapeutics · $6K total across 1 segment · Q2 2021
- License & collaboration revenue$6K—100.0%
Forward guidance
Beam Therapeutics anticipates several milestones in 2024, including advancing multiple base editing programs in the clinic, initiating in vivo clinical studies, and reporting initial data from ex vivo base editing clinical programs.
Tailwinds
- Completing dosing in patients in the sentinel cohort and initiating dosing in patients in the expansion cohort in the first half of 2024 for BEAM-101.
- Reporting initial data on multiple patients from the BEACON trial in the second half of 2024.
- Initiating Phase 1-enabling preclinical studies for the ESCAPE conditioning platform in 2024.
- Initiating a Phase 1 clinical trial for BEAM-302 in the first half of 2024, assuming CTA acceptance.
- Submitting an investigational new drug (IND) application in the U.S. for BEAM-301 in the first half of 2024.
Headwinds
- Risks related to the development, regulatory approval, and commercialization of product candidates.
- Potential inability to raise additional funding.
- Uncertainty in obtaining, maintaining, and enforcing patent and other intellectual property protection.
- Risk that product candidates may not receive regulatory approval necessary to initiate human clinical studies.
- Potential manufacturing or supply interruptions or failures.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+1.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.6%
Avg return
30 days after
56%
14 / 25 earnings
Positive
+21.8%
Q4 2023
Best reaction
-11.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -2.4% | -9.3% | |
| Q4 2025 | +14.1% | +0.5% | -16.6% | |
| Q3 2025 | -6.4% | -8.4% | +19.2% | |
| Q1 2025 | +3.9% | -0.2% | -1.1% | |
| Q4 2024 | -3.1% | -14.5% | -27.9% | |
| Q3 2024 | +9.3% | +11.1% | +3.9% | |
| Q2 2024 | -4.5% | -4.5% | -5.6% | |
| Q1 2024 | -2.4% | -6.7% | +5.7% | |
| Q4 2023 | +21.8% | +11.3% | -7.7% | |
| Q3 2023 | -11.1% | -12.2% | +5.6% | |
| Q2 2023 | +2.2% | +0.0% | -1.5% | |
| Q1 2023 | +1.9% | +4.3% | -6.7% | |
| Q4 2022 | -1.3% | +0.3% | -22.7% | |
| Q3 2022 | -10.3% | +19.0% | +3.0% | |
| Q2 2022 | +3.2% | +8.5% | -10.4% | |
| Q1 2022 | +0.3% | -0.6% | +12.6% | |
| Q4 2021 | -1.7% | -14.3% | -20.5% | |
| Q3 2021 | +9.1% | +2.9% | -11.4% | |
| Q2 2021 | +1.0% | -5.6% | +1.0% | |
| Q1 2021 | +4.3% | +12.2% | +37.1% | |
| Q4 2020 | -4.4% | -5.6% | -22.3% | |
| Q3 2020 | +2.5% | -1.4% | +109.9% | |
| Q2 2020 | -5.1% | -3.5% | +8.6% | |
| Q1 2020 | +3.3% | +3.4% | +23.1% | |
| Q4 2019 | +3.3% | +3.4% | +23.1% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro